Quest PharmaTech (CVE:QPT) Reaches New 12-Month Low – Time to Sell?

Quest PharmaTech Inc. (CVE:QPT)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as C$0.03 and last traded at C$0.03, with a volume of 20000 shares changing hands. The stock had previously closed at C$0.03.

Quest PharmaTech Price Performance

The business’s 50 day simple moving average is C$0.03 and its 200-day simple moving average is C$0.04. The company has a market cap of C$5.07 million, a price-to-earnings ratio of -30.00 and a beta of -0.23. The company has a debt-to-equity ratio of 4.35, a quick ratio of 0.52 and a current ratio of 0.40.

Quest PharmaTech Company Profile

Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.